Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Contrast-induced Nephropathy Clear all
Terminated Phase 4 Interventional Results available

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

NCT00793182
View directory record Official record
Conditions
Renal Impairment
Interventions
Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization

NCT04266834
View directory record Official record
Conditions
AKI, Contrast-induced Nephropathy
Interventions
Experimental Arm
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Not applicable Interventional

Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury

NCT04877847
View directory record Official record
Conditions
Contrast-induced Nephropathy, Chronic Kidney Diseases
Interventions
Low-frequency therapeutic ultrasound (LOTUS), LOTUS System with Ultrasound Disabled
Device
Lead sponsor
Sonogenix
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Detroit, Michigan • Petoskey, Michigan • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study

NCT02669784
View directory record Official record
Conditions
Aortic Aneurysm, Contrast Induced Nephropathy, Aortic and Arterial Anomalies
Interventions
Low Dose Contrast (Omnipaque) 40mL, Low Dose Contrast (Omnipaque) 50 mL
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 24, 2026, 4:03 PM EDT
Not listed Phase 3 Interventional

Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients

NCT01456013
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
RenalGuard Therapy, Standard Therapy
Device · Drug
Lead sponsor
CardioRenal Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 3 Interventional

Prevention of Contrast Renal Injury With Different Hydration Strategies

NCT01218828
View directory record Official record
Conditions
Contrast Medium-induced Nephropathy
Interventions
LVEDP -Based hydration strategy, Standard hydration
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 24, 2026, 4:03 PM EDT
Withdrawn Phase 4 Interventional

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography

NCT00335101
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus
Interventions
Iodixanol, Ioversol, Iopromide
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Contrast Enhanced Ultrasound for Renal Obstruction

NCT05090800
View directory record Official record
Conditions
Kidney; Obstruction, Renal Obstruction
Interventions
Definity contrast during ultrasound
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Phase 3 Interventional

Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease

NCT00930436
View directory record Official record
Conditions
Contrast Induced Kidney Injury.
Interventions
sodium bicarbonate
Drug
Lead sponsor
MD Scientific
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Rome, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Sep 24, 2026, 4:03 PM EDT
Completed No phase listed Observational

Clinical Validation of the RENISCHEM L-FABP POC Assay

NCT04864847
View directory record Official record
Conditions
Acute Kidney Injury, Contrast-induced Nephropathy
Interventions
RENISCHEM L-FABP POC Test
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Chandler, Arizona • Concord, California • Clearwater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Not listed Phase 4 Interventional

Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy

NCT00939913
View directory record Official record
Conditions
Nephropathy
Interventions
intravenous NAC, Placebo
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 4 Interventional

Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)

NCT00289614
View directory record Official record
Conditions
Kidney Diseases
Interventions
Iopamidol 370 mgI/dL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2008 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 4 Interventional

Patients With Renal Impairment Undergoing CT

NCT00292487
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Iopamidol 370 mgI/mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 3 Interventional

Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate

NCT00312117
View directory record Official record
Conditions
Contrast Induced Nephropathy, Kidney Diseases
Interventions
Sodium bicarbonate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure

NCT01252810
View directory record Official record
Conditions
Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
Interventions
GE-145
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
65 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting No phase listed Observational

Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury

NCT07197957
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
BayCare Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Clearwater, Florida • New Port Richey, Florida • Safety Harbor, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 24, 2026, 4:03 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy

NCT01093131
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Oral hydration, Oral sodium bicarbonate, Intravenous Hydration, Intravenous sodium bicarbonate
Other · Drug
Lead sponsor
The Western Pennsylvania Hospital
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of CXA-10 in Healthy Volunteers

NCT02127190
View directory record Official record
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10 emulsion, Placebo
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

NCT05758896
View directory record Official record
Conditions
Contrast Induced Acute Kidney Injury
Interventions
Isuzinaxib (APX-115), Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Not applicable Interventional Results available

Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT

NCT03116139
View directory record Official record
Conditions
Acute Kidney Injury, Pulmonary Embolism, Contrast-induced Nephropathy
Interventions
V/Q imaging, Computed tomography scan
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Indianapolis, Indiana • Royal Oak, Michigan • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 24, 2026, 4:03 PM EDT